Business
Praxis Precision Medicines to Present at Two February Investor Conferences
BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic
About this update from Praxis Precision Medicines, Inc.
[{"type":"text","content":"BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in two upcoming investor conferences: Praxis management will be participating in a fireside chat at the Guggenheim Securities SMID Cap Biotechnology Conference, taking place in New York City on February 6, 2025, at 2:30 p.m. EST. A live webcast of the event will be available through this link.Praxis management will also be participating in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, taking place virtually on February 11, 2025, at 11:20 a.m. EST. A live webcast of the event will be available through this link. The Company will be available for one-on-one meetings during both conferences. Interested investors should contact their respective Guggenheim and/or Oppenheimer representatives to request meetings. Both webcasts will also be available on the “Events and Presentations” page under the “Investors + Media” section of the company’s website. A replay of the webcasts will be available for 90 days. About Praxis Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X. Investor Contact: \nPraxis Precision Medicines \[email protected] \n857-702-9452 \n \nMedia Contact:\nDan Ferry\nLife Science Advisors\[email protected]\n617-430-7576\nSource: Praxis Precision Me...